Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/17/2025 | $35.00 | Buy | The Benchmark Company |
4/29/2024 | $40.00 | Outperform | Leerink Partners |
10/8/2021 | $56.00 → $69.00 | Buy | HC Wainwright & Co. |
9/9/2021 | $60.00 → $56.00 | Buy | Aegis Capital |
9/7/2021 | $22.00 | Outperform → Neutral | Wedbush |
9/7/2021 | $22.00 | Neutral → Underperform | Wedbush |
6/29/2021 | $60.00 | Buy | Aegis Capital |
Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms Further Adjourns Special Meeting to October 3, 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 24, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX) today announced that it has reached an agreement to amend its previously announced Business Combination Agreement (the "Amended Agreement") with XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company. XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) continues to act as structuring agent and intends to provide financing for the transac
WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural"), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2022 (the "Irish Takeover Rules"), that it has published the definitive proxy statement of Mural relating to the Acquisition described below, which also constitutes a scheme circular under Irish law (the "Proxy Statement") and that Mural has commenced mailing the Proxy Statement to Mural shareholders. As previously announced on August 20, 2025, XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty") and Mural entered into a definitive transaction
EMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about October 15, 2025, t
4 - XOMA Royalty Corp (0000791908) (Issuer)
4 - XOMA Royalty Corp (0000791908) (Issuer)
4 - XOMA Royalty Corp (0000791908) (Issuer)
The Benchmark Company initiated coverage of XOMA Royalty Corporation with a rating of Buy and set a new price target of $35.00
Leerink Partners initiated coverage of XOMA with a rating of Outperform and set a new price target of $40.00
HC Wainwright & Co. reiterated coverage of XOMA with a rating of Buy and set a new price target of $69.00 from $56.00 previously
4 - XOMA Royalty Corp (0000791908) (Issuer)
4 - XOMA Royalty Corp (0000791908) (Issuer)
4 - XOMA Royalty Corp (0000791908) (Issuer)
8-K - XOMA Royalty Corp (0000791908) (Filer)
8-K - XOMA Royalty Corp (0000791908) (Filer)
8-K - XOMA Royalty Corp (0000791908) (Filer)
SC 13G/A - XOMA Corp (0000791908) (Subject)
SC 13D/A - XOMA Corp (0000791908) (Subject)
SC 13G/A - XOMA Corp (0000791908) (Subject)
EMERYVILLE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about October 15, 2025, t
WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company ("Mural"), and XOMA Royalty Corporation (NASDAQ:XOMA), a biotechnology royalty aggregator ("XOMA Royalty"), announced today they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty ("Sub"), has agreed to acquire the entire issued and to be issued share capital of Mural for cash (the "Acquisition") subject to the satisfaction of the closing conditions set out in Appendix I of this Announcement (the "Conditions"), including approval by Mural Shareholders. Fol
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) announced today they have entered a definitive share purchase agreement (the "Purchase Agreement" and the transactions set forth in the Purchase Agreement, the "Transactions") whereby XOMA Royalty will acquire LAVA for (i) between $1.16 and $1.24 per share in cash, consisting of (A) USD $1.16 (the "Base Price Per Share") in cash per share (the "LAVA common stock"), plus (B) an additional amount of cash of up to $0.08 per Share (such amount as finally determined in accordance with the Pur
Earned $9 million milestone upon U.S. Food and Drug Administration's approval of Day One's OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA's balance sheet Expanded the commercial royalty and milestone portfolio with the acquisitions of economic interests in DSUVIA® (sufentanil sublingual tablet) and XACIATO™ (clindamycin phosphate) vaginal gel 2%, as well as two Phase 3 assets Launched XOMA's first stock repurchase program for up to $50 million EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royal
BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.
EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board. Mr. Hughes has served as XOMA's Executive Chairman and Interim Chief Executive Officer since January 1, 2023. "The rest of the Board and I have been impressed with Owen's leadership over the past year and his vision to establish XOMA as the premiere biotech royalty aggregator. I am looking forward to working closely with Owen and the team to further accelerate the Company's growth and maximize value for all XOMA stockholders," stated